Should subchondral bone turnover be targeted when treating osteoarthritis?  by Karsdal, M.A. et al.
Osteoarthritis and Cartilage (2008) 16, 638e646






Should subchondral bone turnover be targeted when treating
osteoarthritis?
M. A. Karsdal M.Sc., Ph.D.y*, D. J. Leeming M.Sc.y, E. B. Dam M.Sc., Ph.D.y,
K. Henriksen M.Sc., Ph.D.y, P. Alexandersen M.Sc., Ph.D.z, P. Pastoureau Ph.D.x,
R. D. Altman M.D.k and C. Christiansen M.D.y
yNordic Bioscience A/S, Herlev, Denmark
zCenter for Clinical and Basic Research, Ballerup Byvej 222, Ballerup, Denmark
x Institut de Recherche Servier (IdRS), Paris, France
kDavid Geffen School of Medicine, University of California-Los Angeles, Los Angeles, USA
Summary
Objective: Osteoarthritis (OA) is the most common form of arthritic disease, and it is a major cause of disability and impaired quality of life in
the elderly. OA is a complex disease of the entire joint, including bone and cartilage, thereby presenting alternative approaches for treatment.
This review summarizes emerging observations from cell biology to preliminary clinical trials, describing interactions between the bone and
cartilage components. We speculate whether a treatment for OA would be possible without targeting the bone compartment?
Methods: Peer-reviewed articles found using pre-deﬁned search criteria and published in the PubMed database until June 2007 are summa-
rized. In addition, abstracts from the OsteoArthritis Research Society International (OARSI) conferences in the time period 2000e2007 were
included.
Results: Bone and cartilage health seem to be tightly associated. Ample evidence is found for bone changes during progression of OA,
including, but not limited to, increased turnover in the subchondral bone, thinning of the trabecular structure, osteophytes, bone marrow
lesions and sclerosis of the subchondral plate. In addition, a range of investigations has described secondary positive effects on cartilage
health when bone resorption was suppressed, or deterioration of the cartilage when resorption is increased.
Conclusion: An optimal treatment for OA might include targeting both the bone and cartilage compartments. Hence, as several cell systems
are to be targeted in a safe manner, limited options seem possible.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is the most common form of arthritis1. A
hallmark of the disease is progressive degeneration of
articular cartilage and subsequent joint space narrowing
(JSN).
Experimental and clinical observations suggest that the
structural integrity of articular cartilage is dependent on
normal subchondral bone turnover, intact chondrocyte func-
tion and ordinary biomechanical stresses2,3. An increasing
line of evidence suggests that there are strong inter-
relationships between the subchondral bone and the articu-
lar cartilage. Therefore, in the face of normal biomechanical
stresses, an ideal therapeutic agent might logically be
directed at regulating the metabolic activity of both bone
and cartilage.
In the majority of patients, the etiology of OA is not
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638signiﬁcant traumata, obesity, altered gait, altered biome-
chanics (e.g., varus or valgus deformity), and excessive loa-
ding4e7. Several lines of data indicate that OA could result
from a metabolic component as evidenced by the ﬁnding
that the decreased sex hormone levels in both animal
models and women are associated with increased cartilage
degradation, in addition to the well described increase in
bone turnover8e12. Furthermore, the increased bone turn-
over leads to altered composition and biomechanical prop-
erties, which could exuberate the pathogenesis of OA13e18.
Most of these studies were realized in humans and
focused on late and end-stage disease, which reveals little
about early deregulation of cartilage and bone turnover.
However, a biochemical investigation of the circulating
levels of macromolecules released from cartilage and
bone in serum, during the early stage of OA in humans,
suggests that pathological processes in cartilage and
subchondral bone coincide in OA19. From this, there is an
obvious interest in studying early bone and cartilage events
in animal models and in clinical settings.
The use of biochemical markers has recently been
proposed as a supplement to classical imaging techniques
for improved diagnosis, and for monitoring of disease
639Osteoarthritis and Cartilage Vol. 16, No. 6progression in studies of OA20. These provide dynamic
measures, in contrast to imaging techniques that offer
‘‘snap-shots’’ of the current disease state. These novel
techniques have aided in understanding the dynamics of
bone and cartilage turnover, and could reveal possible
metabolic processes in OA.
In this review we have focused on the role of the bone
compartment in OA, and the apparent coupling between
cartilage and bone turnover. We have taken into account
experimental observations from pre-clinical and clinical
studies, including interventions affecting both the bone
and cartilage compartments.
Based on this evidence, the question becomes: ‘‘Is it
possible to inhibit cartilage health deterioration without
targeting the joint as a whole organ, thereby involving mul-
tiple cell types, but most importantly both osteoclasts and
chondrocytes?’’ Having this difﬁcult scene set for ﬁnding
a possible disease modifying drug for OA, targeting several
cell systems in a safe manner, only a limited number of
options seem possible.Methods
The PubMed database until September 2007 was searched, using the
following search terms: cartilage, OA, subchondral, sclerosis, bone, biome-
chanical. In addition, articles were reviewed for other relevant references.
Additional studies were found in a review of abstracts from the OsteoArthritis
Research Society International (OARSI) conferences in the time period
2000e2006.ResultsTHE ROLE OF SUBCHONDRAL BONE TURNOVER
AND STRUCTURE IN OAThe relationship between bone and cartilage degradation
in OA is complex, although an apparent co-existence
between the two processes is present at a macroscopic
observation scale2.
Examinations of peri-articular bone in knees and hips of
patients with OA have conﬁrmed that the subchondral
bone is abnormal in OA joints, with altered trabecular
structure and sclerosis of the subchondral plate21,22. Bone
scintigraphy has revealed localization of the nuclide to sites
of increased subchondral bone turnover23. Cross-sectional
studies have also established that women with advancedFig. 1. Schematic illustration of the alterations in the subchondral area. R
plateau, showing loss of cartilage, increased bone turnover, sclerosis ofknee or hip OA have higher bone mineral densities
(BMDs) near, or at the site of joint OA24. In fact, subchon-
dral bone turnover has been shown to be as much as 20-
fold increased compared to that of normal bone turnover14.
Studies using anterior cruciate ligament transection
(ACLT) in dogs as wells as meniscectomy (MNX) and
ACLT in rat have provided instrumental information on the
role of subchondral bone changes in OA25e27. During
progression of OA the subchondral bone gradually
becomes sclerotic, with bone formation in the periphery of
the articular cartilage plate, both laterally and medially,
resulting in osteophytes2. In addition, trabecular bone in
the subchondral regions is thinned and elasticity is
lost25,27,28. Findings, which have been speculated to be
important for OA progression25,27,28. This combination
of changes in the bone matrix are important features in
the pathology of OA, although they are thought to be
secondary effects caused by the loss of articular
cartilage2,3,13e17,26,29e33. This is sought illustrated in Fig. 1.
Subchondral bone is separated from the articular carti-
lage only by a layer of calciﬁed cartilage34. This allows for
several possibilities of transmitting signals from one
compartment to the other. Among these are increased
vascularization, and the development of microcracks occur-
ring in the bone matrix, both phenomena which have been
strongly implicated in initiation of bone remodeling, as well
as increased degradation of the calciﬁed cartilage34,35. In
alignment, in race horses, micro-crack propagation in the
calciﬁed cartilage and subchondral bones, was speculated
to be involved in the initiation of articular cartilage break-
down, and thereby initiation and progression of OA36e38.
Subchondral bone turnover may logically depend on
osteoclastic activities. Osteoclasts have been shown to
play important roles in the degradation of cartilage in rheu-
matoid arthritis (RA)39e42, whereas the role of osteoclasts
in the pathogenesis of OA still needs more attention. Sup-
port for the important role of osteoclast function and bone
turnover in the pathogenesis of OA, recently came from an
animal model of OA, where extensive inhibition of bone re-
sorption resulted in a 50% decrease in cartilage pathology
score, using the golden standard Mankin score3,26. In addi-
tion, a bone densitometric evaluation in the meniscectom-
ized guinea pig model of OA revealed typical variations
of bone metabolism in the initiation of the OA pathology
with an early bone loss at the subchondral level followedight panel A: normal tibial plateau. Left panel B: osteoarthritic tibial
the subchondral plate, thinning of the trabeculae, and osteophytes.
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previous extensive ﬁndings of altered subchondral turnover
in the pathogenesis of OA13e17,29,44. In alignment, acceler-
ated bone turnover, in both traumatic and estrogen deﬁ-
ciency models [ovariectomy (OVX)], in which increased
bone resorption alone results in increased articular dam-
age31 has been shown to augment articular cartilage
erosion9e12,30. Finally, evidence from the DunkineHartley
guinea pig model indicates that subchondral changes
precede the changes in the cartilage45,46, thereby further
supporting a role for bone remodeling in the development
of OA.
Taken together, bone turnover and osteoclast functions
are important elements in the pathogenesis of OA, in which
both osteoclastic bone resorption and signals coming from
osteoclasts may play important roles47 in the different
sclerotic and osteoporotic and sub-compartments of bone.ALTERATIONS IN THE OSTEOBLAST, OSTEOCLAST AND BONE
PHENOTYPES IN THE PATHOGENESIS OF OAWhereas on a macroscopic observational scale there is
an almost obvious coupling of bone and cartilage proces-
sed13e17,29, the cellular and molecular mechanisms remain
to be further investigated and identiﬁed.
Recently, TGF-b signaling which is known to play several
important roles in bone and cartilage, was suggested to be in-
volved in the coupling between bone and cartilage
turnover3,13,29. Furthermore, interleukin (IL)-6 has also
been implicated in the cross-talk between bone and cartilage,
and studies have shown that IL-6 in combination with other
cytokines can switch osteoblasts from a normal phenotype
to a sclerotic phenotype48, as well as altering expression of
different chemokines, such as regulated on activation, nor-
mal T cell expressed and secreted (RANTES) and monocyte
chemoattractant protein (MCP-1)49. In addition, male IL-6 de-
ﬁcient mice shown increased age-related OA50, further indi-
cating that IL-6 plays a role in OA. However, the present
understanding remains on an observational level, in which
an increasing range of experimental evidence is emerging.
With respect to changes at the molecular level, osteoar-
thritic bone matrix in the subchondral plate has been shown
to have alterations in collagen turnover and structure,
cytokine expression, as well as mineralization17,51. In this,
OA results in increased bone formation, assessed by
Alkaline Phosphatase and levels of C-terminal pro-peptide
of type I collagen (PICP)29 and associated hypomineralized
bone, indicating compromised structural integrity29. The
compromised bone integrity was corroborated by Bailey
et al. who demonstrated that the composition of collagen tri-
mers was altered towards homotrimers of the alpha1 chain,
which are associated with lower tensile strength52. In addi-
tion, the hydroxylation of the lysines was increased leading
to increased cross-linking, further contorting the collagen
structure52, and not surprisingly the bone matrix was dem-
onstrated to have impaired mechanical strength53, despite
the increased density.
With regards to the cellular phenotype, only little informa-
tion is available. Experiments performed using isolated
osteoblasts form OA patients have shown increased proteo-
glycan degradation in cartilage, in contrast to healthy
controls54. This has been suggested to be a result of
increased matrix metalloproteinase (MMP)-2 expression of
these bones29. This may indicate a role for altered osteo-
blast phenotypes during disease development, resulting in
the above-described alterations in matrix function and com-
position. In addition, a group has shown that osteoblastsfrom the sclerotic regions of bone isolated from OA patients
could be involved in induction of chondrocyte hypertro-
phy55. Furthermore, the same group also demonstrated
that the sclerotic osteoblasts were capable of switching
the proﬁle of chondrocytes towards cartilage degradation,
as illustrated by a reduction in aggrecan production, but
an upregulation of MMP production48. Finally, a study
showed that the bone remodeling rates in healthy individ-
uals correlate to receptor activator of nuclear factor-kappaB
ligand (RANKL) expression levels, whereas in OA patients
this correlation is no longer existing56. As osteoblasts are
a major source of RANKL57,58, this further supports the
view that changes in osteoblasts are involved in OA pathol-
ogy and progression.
With respect to the phenotype of osteoclasts in the
pathogenesis of OA, only sparse information is available.
Recently, a study showed that a powerful anti-resorptive,
the bisphosphonate alendronate, suppressed cartilage
degradation and formation of osteophytes in a rat model,
an effect most likely mediated via a reduction in osteoclast
numbers and activity3. In this, alendronate treatment
reduced the release of TGF-b3, a cytokine which is present
at abnormally high levels in OA59, and speculated to be
important in the coupling of cartilage and bone turnover13.
The exact role and phenotype of osteoclasts in the develop-
ment of OA needs attention. It is of major interest to inves-
tigate whether the osteoclasts involved in the development
of OA, indeed are authentic osteoclasts or chondroclasts,
i.e., whether osteoclasts localized on calciﬁed cartilage in
the subchondral bone are different from those on normal
bone matrix, as these may not be identical60,61. Drawing
a parallel to rheumatoid arthritis (RA), which is character-
ized by excessive osteoclast function, and in models of
RA, anti-osteoclastic treatments, such anti-RANKL
approaches, reduce the extent of the disease42,62.
Taken together, it appears that osteoclastic bone resorp-
tion, bone formation by the osteoblasts, and signals coming
from both osteoclasts and osteoblasts may play important
roles in the mal-metabolism of the subchondral bone during
pathogenesis of OA13,47.A POSSIBLE BIOMECHANICAL COUPLING OF BONE
AND CARTILAGEThe possible coupling between bone and cartilage has
also been investigated using novel magnetic resonance im-
aging (MRI) techniques. MRI has been validated for analy-
sis of trabecular structure by comparison to mCT, in which in
particular 3 T imaging has demonstrated a high correlation
between MRI and mCT based measures63,64. Blumenkrantz
et al. undertook MRI analyses, which were applied to com-
pare longitudinal changes in bone density and quality, as-
sessed by apparent trabecular structure, which were
correlated to changes in cartilage volume and quality63.
They concluded that there was a positive correlation be-
tween cartilage loss and localized bone changes closest
to the joint line, speciﬁcally; the cartilage loss and the de-
crease in apparent trabecular count were correlated in
both the medial (r¼ 0.36, P< 0.05) and the lateral
(r¼ 0.41, P< 0.05) tibial chondyles. Furthermore, negative
correlations were observed with the bone changes farthest
from the joint line (e.g., the medial tibial cartilage volume
was negatively correlated with the apparent bone volume
fraction of the tibia, r¼0.53, P< 0.05). They hypothe-
sized that cartilage degeneration coincides locally with sub-
chondral bone sclerosis, which then causes subchondral
641Osteoarthritis and Cartilage Vol. 16, No. 6bone osteopenia due to decreased load transmission64. Re-
active bone formation may then occur farther away from the
cartilage abnormality in order to compensate for the local-
ized bone loss.
Applying the same methodology, Lindsey and colleagues
found that cartilage loss in the medial compartment directly
correlated to bone formation in the medial chondyle, and to
bone resorption in the lateral compartment. Speciﬁcally, the
medial tibial cartilage volume was positively correlated to
lateral apparent trabecular count (r¼ 0.33, P¼ 0.005)65.
This relationship is illustrated in Fig. 2. Furthermore, by
analyzing differences between lateral/medial measure-
ments, they hypothesized that these cross-compartmental
relationships are consistent with biomechanical changes
in load distribution caused by varus mal-alignment. Using
conventional radiographs Messent et al. presented similar
ﬁndings. From knee macro-radiographs of 40 patients,
they demonstrated that JSN was associated with
a decrease of the subchondral trabecular number66. They
hypothesized that thickening of the cortical plate; occurring
before JSN, caused a load redistribution that reduced the
subarticular stress leading to osteoporosis (OP).
These studies support a biomechanical coupling relation-
ship between cartilage and bone in OA, although they do
not provide clear indications of the causal relationship.
The observation that cortical thickening occurs before
JSN does not necessarily imply that bone changes are prior
to cartilage changes, since JSN occurs relatively late in the
evolution of OA. However, these studies do provide
additional support for the close spatial and temporal
relationship between bone and cartilage.METABOLIC OAMetabolic OA, showing a systemic increased turnover of
cartilage, is found in postmenopausal women in whom OA
is more pronounced, than in the pre-menopausal popula-
tion8,67e70. An epidemiological study supports the concept
that women, in addition to age, are at a higher risk than
men71. This indirectly supports the hypothesis that sex
hormones are related to the incidence of OA. In addition,
experimental studies in monkeys30,31 and rats72 have
shown that estrogen depletion results in increased bone
turnover, and accelerated cartilage breakdown. These
observations are somewhat complicated by the fact that
chondrocytes have been shown to express estrogen recep-
tors73e75, and respond to estrogen intervention76, however,Fig. 2. Biomechanical coupling: medial cartilage loss is correlated to loss
coupling between bone and cartilage. Illuit is not believed that this accounts for the entire detrimental
effect of estrogen loss on cartilage health77.
A relationshipbetweenOPandOAhasbeendemonstrated
in female rabbits9. Here induction ofOAwasperformed byan-
terior cruciate section and partial medial MNX in 12 animals,
and OP by OVX in six of these prior to OA induction. OP in-
creased the severity of OA compared to animals without OP
and an inverse correlation was observed between BMD at
the lumbar spine and cartilage damage deﬁned as increased
Mankin scoring. These data indicate that a higher bone turn-
over exuberates the OA characteristics. In alignment, devel-
opment of OA was followed in mice having destabilization of
themedialmeniscus (DMM).Half of theseanimalswereorchi-
ectomized (ORX, malemice) or OVX (femalemice)10. OA se-
verity was markedly higher in DMM male mice than DMM
female mice. However, OVX female mice developed more
severe OA compared to controls, whereas ORX male mice
develop signiﬁcant less severe OA than control mice.
Taken together, this compilation of data indicates that
increases in bone turnover, due to sex hormone deﬁciency,
play a critical role in the progression of OA in both mouse
models and humans, even though potential direct hormone
effects on the chondrocytes cannot be ruled out.BIOCHEMICAL MARKERS OF BONE AND CARTILAGE
TURNOVERBone and cartilage degradation can be measured by
biochemical markers, such as bone resorption by cross-
linked C-terminal type I collagen fragments (CTX-I),
reﬂecting type I collagen78 and cartilage degradation by
CTX-II, reﬂecting type II collagen79. These markers have
been used extensively for the evaluation of these para-
meters in basic, experimental and clinical studies20.
In a subgroup of the OFELY (Os des Femmes de Lyon)
study, 435 healthy untreated younger postmenopausal
women were followed for 5 years to predict the risk of
fracture80. Women in the highest quartile of baseline bone
marker level were found to have a relative risk of fracture
of 2.1, emphasizing the relevance and importance of the
biochemical markers of bone turnover. With respect to
cartilage degradation and the use of biochemical markers,
a cross-sectional and longitudinal study of 1235 men and
women from Rotterdam examined the association between
CTX-II and the radiographic prevalence and progression of
OA in the knee and hip81. Subjects with CTX-II levels in the
highest quartile at baseline had a 4.2-fold increased risk ofof lateral trabecular structure65 revealing a potential biomechanical
stration inspired by Lindsey et al.65
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to subjects in the lowest quartile. The risk of disease
progression was 6.0-fold increased in the knee and 8.4-
fold increased in the hip of the same patients determined
at follow-up. Thus, the highest risk of OA and progression
was found in patients with the highest baseline levels of
CTX-II. A similar ﬁnding, namely that those individual with
the highest CTX-II levels had the highest odds ratio for having
OA was validated in the genetics, arthrosis and progression
(GARP) study of sibling pairs, in which symptomatic OA
and the levels of a number of biochemical markers were as-
sessed82. Results showed a direct correlation between
CTX-II and radiographic signs of OA in signals joints
(P< 0.001)48, and that those with the highest CTX-II levels
had a 7.7 increased odd ratio for having OA.
Taken together, biochemical markers of bone and
cartilage destruction may be valuable for the interpretations
of the biological processes and for determining the
sequence of bone and cartilage changes, leading to a better
understanding of disease progression in OA.ANTI-RESORPTIVE STRATEGIES IN OA: NON-CLINICAL
STUDIES AND ANTI-RESORPTIVE TREATMENTSAn alternative approach to investigate the coupling
between bone and cartilage turnover and deterioration in
the pathogenesis in OA is through analysis of the response
to various treatments in both pre-clinical and clinical stud-
ies. A 3-year study examined the effect of anti-resorptive
estrogen replacement therapy (ERT) for the prevention of
OA in 180 female cynomolgus monkeys30,31. Ovariecto-
mized adult monkeys were divided into groups receiving
ERT or receiving no treatment. Signiﬁcantly fewer cartilage
lesions of OA were seen in the ERT group compared to the
control group, as evaluated by quantitative histology. The
authors suggested that high bone turnover co-equals high
risk for cartilage degradation and that exogenous estrogens
may confer protection against the development of OA. As
mentioned previously, Duong and colleagues investigated
the effects of bone turnover and development of OA by
the use of intravenous (i.v.) bisphosphonate treatment in
a traumatic model of OA, the ACLT model3,26. Bisphospho-
nate treatment resulted in a 50% decrease in disease
severity scores OA, further emphasizing the importance
and coupling between bone and cartilage health.
Additional support for the role of the subchondral bonewas
found in studies examining the effect of calcitonin in ACLT
dogs. Calcitonin signiﬁcantly affected trabecular structure
and prevented subchondral bone resorption and trabecular
thinning, which was speculated to a major factor in the
reduced cartilage degradation83e85. The mode of action of
calcitonin may be different compared to that of other anti-re-
sorptives, as calcitonin was demonstrated to have both direct
and indirect actions on articular cartilage83e95. In golden
standard traumatic and non-traumatic animal models of
OA, i.e., the dog ACLT model, calcitonin has been demon-
strated to have positive effects on articular cartilage surface
erosion andbonestructure aswell as increasedproteoglycan
content of the articular cartilage84,86,95,96.
Taken together, this increasing line of evidence, points
toward the fact that that some anti-resorptive treatments,
such as bisphosphonates, calcitonin, estrogen or selec-
tive estrogen-receptor modulators (SERMs) have positive
effects on both cartilage and bone degradation, possibly
due to a tight coupling between these compartments.
Some of these possible intervention options may, in addi-
tion to the effects on osteoclasts and bone turnover,provide additional beneﬁts by targeting chondrocytes
directly.ANTI-RESORPTIVE STRATEGIES IN OA: CLINICAL STUDIESA number of studies have investigated the coupling
between bone and cartilage degradation. We have previ-
ously demonstrated the therapeutical beneﬁt of a SERM,
levormeloxifene, in 301 postmenopausal women from
a phase II trial, for the prevention of both bone loss and car-
tilage degradation by restoring levels to that of the pre-men-
opausal level during a 12-month period12. Both cartilage
and bone degradation assessed by CTX-II and CTX-I
were decreased by approximately 50% in the treatment
groups compared to baseline. After treatment cessation
CTX-II reversed back to baseline values, indicating
a short-term effect of the SERM on the cartilage as
compared to that on bone. Similarly, another group found
that cartilage degradation in 384 postmenopausal women
was signiﬁcantly lower in women using HRT compared to
women not receiving hormone replacement therapy
(HRT)8. Additionally, groups receiving between 4 and 10
years of HRT had signiﬁcant lower CTX-II than those re-
ceiving less than 4 years of treatment. It was observed
that degradation was signiﬁcantly higher in postmenopausal
women compared to an age-matched group of pre-meno-
pausal women.
Effects of calcitonin on both bone and cartilage have raised
interest in using it as a therapy forOA. Calcitoninwas demon-
strated to have chondroprotective effects in two different
clinical trials93,96. In these, calcitonin showed both effects
on pain scores, and biochemical markers of cartilage degra-
dation. However, additional clinical studies are needed to
further investigate and validate these ﬁndings.
In some instances administration of anti-resorptive drugs
to patients cause a decrease in both cartilage degradation
and bone resorption8,12,97. In therapy of Paget’s disease,
one dose intravenously administered zoledronate resulted
in a reduction of CTX-II and CTX-I at 1 month97. At base-
line, CTX-II levels were not elevated compared to a group
of age-matched healthy controls. This was in contrast to
a ninefold increase in CTX-I compared to controls. Five
days after a single 4-mg dose of zoledronate, CTX-II
decreased by a median of 25% and then increased to
pre-treatment levels 10 days after injection. CTX-I
decreased a maximum of 51% at day 10 and levels
remained suppressed during the 2 months of the study
indicating that zoledronate has a long-term effect on bone
resorption as well as a short-term effect on cartilage. This
is in contrast of the effect of oral bisphosphonates in which
a long-term effect on both and cartilage is observed98,99.
Thus, different anti-resorptive agents, and even routes
of administration, appear to have different effects on
cartilage.Discussion
The potential coupling and uncoupling of bone and
cartilage turnover are illustrated in Fig. 3. Under physiolog-
ical conditions, bone and cartilage turnover are coupled.
Increased bone resorption can exist together with increased
cartilage degradation, but within the normal biological
variation. Under pathological conditions of extremely high
turnover, such as bone metastasis, bone resorption is
highly elevated, although cartilage degradation is only
minutely affected, thus these processes are uncoupled.
Fig. 3. Schematic ﬁgure showing the coupling/uncoupling relation-
ship between cartilage and bone. Under normal physiological
conditions, bone and cartilage turnover are coupled (lower left
quadrant). In bone metastasis where pathologically increased
bone turnover is observed, cartilage turnover is only minimally
affected. In contrast, in postmenopausal OA both bone and carti-
lage are increased, probably due to increased metabolic activity
in subchondral bone. Some anti-resorptive agents, such as estro-
gens, SERMs, bisphosphonates, and calcitonin inhibit increased
bone turnover and also the increased cartilage turnover, in part
through direct interaction of attenuating subchondral bone turnover,
and possibly by direct action receptors activated action on chondro-
cytes. Additional data on anti-RANKL and strontium ranelate are
needed in order to correctly incorporate them into this model.
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resorption can be restored to normal levels, whereas
cartilage degradation is only vaguely affected97.
In contrast, during postmenopausal increased high
turnover, both bone resorption and bone formation can be
restored back to normal levels. HRT will restore both
levels to pre-menopausal levels, whereas a SERM will
have lower efﬁcacy on bone. In alignment, treatment with bi-
sphosphonates will suppress bone resorption to lower
levels than cartilage degradation.
Presence and activation of osteoclasts seem to be
involved in the pathogenesis of OA and other cartilage
degenerative diseases41,42. Increased expression of osteo-
clast differentiation factors RANKL is known to occur in the
synovial membrane of chronically OA joints, leading to
secondary bone resorption39,100. In similar context, another
group recently investigated the expression of bone resorp-
tion genes in OA and OP, in relation to differences in
RANKL regulation of proteases101. In this, cathepsin K,
MMP-9 and tartrate resistant acid phosphatase (TRACP)
mRNA were transcribed at higher levels per given RANKL
expression in the OA group compared to that in the fracture
(OP) group101. This may indicate that blockade of osteo-
clast formation may constitute a potential target in prevent-
ing the structural damage seen in OA. Novel monoclonal
antibodies neutralizing the RANKL may prove interesting
in preventing both OP and OA-associated bone loss, but
at present clinical data are sparse. In alignment, the re-
cently approved anti-resorptive strategy strontium ranelate,
might in addition have beneﬁcial effects on cartilage health,
although the anti-resorptive effect compared to that of anti-
RANKL, SERMs, calcitonin and bisphosphonates is
lower102.
This compilation of evidence suggests that bone and
cartilage turnover are tightly associated, and that someselected anti-resorptive treatments may have additional
beneﬁts on cartilage health. Does this suggest that stimula-
tion of bone formation may have adverse effects? Bone
sclerosis is an important part of the pathogenesis of
OA103e107, that leads to deformation of the articular
surfaces and absorption of local stresses producing an
effect similar to stress-shielding that may augment OA
progression. Recently wnt signaling was shown to be
essential for osteophyte generation40, and bone sclerosis
in an animal model of cartilage destruction. In addition,
upregulation of genes in the wnt family has also been
observed108. Finally, there is evidence indicating that low-
density lipoprotein receptor-related protein (LRP)5 haplo-
types are associated with OA109,110. An increasing amount
of attention is focused on bone anabolic drugs, with special
emphasis on wnt enhanced signaling. Will these interven-
tions be associated with augmented OA symptoms and dis-
ease progression? These important questions of safety
need to be addressed in future studies speciﬁcally designed
for that purpose.
Due to the unmet medical need and the widespread na-
ture of OA, it is urgent to develop safe and effective disease
modifying treatments for patients with OA. Ample evidence
is found for a tight local coupling between bone and carti-
lage. Thus, an optimal treatment option for OA would entail
both bone and cartilage protective effects. However, with
this information limited options seem possible. Some estro-
gens compounds and calcitonin may provide this dual ac-
tions approach, however, still more clinical research is
needed.Conﬂict of interest
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